Merus N.V. (NASDAQ:MRUS) Receives $93.56 Average PT from Brokerages

Shares of Merus N.V. (NASDAQ:MRUS) have earned an average recommendation of “Hold” from the eighteen ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $93.5625.

Several brokerages have recently commented on MRUS. Wells Fargo & Company reiterated an “equal weight” rating and issued a $97.00 target price (up previously from $95.00) on shares of Merus in a report on Monday, September 29th. UBS Group lowered shares of Merus from a “buy” rating to a “neutral” rating and increased their price objective for the company from $72.00 to $97.00 in a research note on Tuesday, September 30th. Leerink Partners reissued a “market perform” rating and set a $97.00 target price (up previously from $95.00) on shares of Merus in a research report on Monday, October 6th. Alliance Global Partners assumed coverage on Merus in a report on Monday, August 25th. They issued a “buy” rating and a $90.00 target price for the company. Finally, HC Wainwright lowered Merus from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $135.00 to $97.00 in a report on Monday, September 29th.

Insider Activity at Merus

In related news, VP Harry Shuman sold 1,700 shares of the business’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $96.10, for a total value of $163,370.00. Following the transaction, the vice president directly owned 11,002 shares of the company’s stock, valued at approximately $1,057,292.20. The trade was a 13.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.70% of the stock is owned by insiders.

Institutional Trading of Merus

Several hedge funds have recently added to or reduced their stakes in MRUS. CWM LLC boosted its stake in Merus by 299.0% in the second quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 601 shares during the last quarter. Quarry LP bought a new stake in shares of Merus in the third quarter valued at $42,000. Farther Finance Advisors LLC raised its stake in shares of Merus by 10,400.0% in the third quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 520 shares during the period. Longfellow Investment Management Co. LLC purchased a new position in shares of Merus during the 3rd quarter valued at $75,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 1,624 shares during the period. Institutional investors own 96.14% of the company’s stock.

Merus Stock Down 0.0%

Shares of NASDAQ:MRUS opened at $96.89 on Friday. The business’s 50 day moving average is $95.57 and its 200 day moving average is $75.41. Merus has a 12-month low of $33.19 and a 12-month high of $96.99. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of -18.28 and a beta of 1.06.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.